Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've been holding for a while myself. We need something besides Dutchess to talk about for tomorrow. I don't think we will hear any earth shattering news myself. Hope I'm wrong. JMO
Any volume here is good volume. There has been such limited trading action here for the longest. There is such a tight float here. Anything possitive and this could rocket. JMO
Tons of accumulation going on here. Very nice to see.
I'm hearing that we should expect big things next week. We should hold on to our hats. JMO
I hope it gets there. When I first bought this stock, i thought I would see that price rather quickly. Its been a few long years since.
Ferris always keeps info close to his vest. This our chance to try and pry some info from him. We all waited along time, its time to be paid for our patience.
Not even one trade based on the news the released last night. Very interesting to me. Does anyone else feel we we hear news about the Dutchess debt being retired prior to the conference call?
Looks like flippers are getting out. This stock moves on such light volume.
Glad to see your still here. There has been way to much negativity here. Slow and steady wins the race. Patience is the key.
Where's Sirfelix been. Are you o longer a shareholder here anymore?? This is turning ugly fast.
It sure looks that way. With China and the US markets becoming available this year, the potential is there. JMO
Very nice move indeed. There are some good things going on here. Just need to keep getting the word out. This stock has been way undervalued for too long.
Slow and steady wins the race. This new "old " addition to the board is a great development.
Were getting some nice action here lately. Any thoughts?
Update from Watson
Watson has high hopes for Stellar’s Uracyst drug
March 31, 2010 by leonardzehr · Leave a Comment
Watson Pharmaceuticals (NYSE:WPI) CEO, Paul Bisaro, painted a rosy picture of how Stellar Pharmaceuticals’ (OTCBB: SLXCF (SLXCF 1.03 ?8.42%)) Uracyst drug, which is indicated to treat interstitial cystitis, fills out its urology strategy.
According to a presentation at a healthcare conference sponsored by Barclays Capital, Mr. Bisaro said that Watson’s strategy is based on the 10 most common reasons why people go to an urologist, everything from benign prostatic hyperplasia to cystitis, and “we look at basically each of the target areas and want to fill out our pipeline accordingly.”
Treating cystitis represents a “sort of low bar” currently with a market value of around $500 million (U.S.) in annual sales, he pointed out.
“Part of that is because there isn’t really an effective treatment for cystitis. We think if Uracyst is successful, we will see that bar grow, and we will be the beneficiary of that bar.” Watson’s clinical testing with Uracyst is now at the end of Phase 2, he added.
At the end of 2006, Watson licensed the U.S. rights for Uracyst from Stellar, which currently sells the product direct in Canada and through out-licensing agreements in the rest of the world.
Looks like we are getting a little more action. Stellar is very well positioned going forward. Health care reform will have minimal to no affect on them. The key is getting Fda approval which should occur this yr. Jmo
Where's SirFelix been??
Why is Hdsn buying right now? hummm jmo
I agree with you there. Lets hope more people can see what we see. Gl as well.
Hey Db7 what do you know about our loveable Stellar?? This company IMO is way undervalued and under exposed.
Is this accumulation?? Does anyone have an idea on how to spread the word?
crickets.....
Earnings Out.
Stellar Pharmaceuticals Profitable for 2009
Buzz up! 0
Print
Press Release Source: Stellar Pharmaceuticals Inc. On Wednesday March 17, 2010, 7:30 am EDT
LONDON, ONTARIO--(Marketwire - 03/17/10) - Stellar Pharmaceuticals Inc. (OTC.BB:SLXCF - News) ("Stellar" or "the Company"), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced financial results for the year ended December 31, 2009. In this press release, all dollar amounts are expressed in Canadian currency and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
2009 Highlights
-- Revenues grew by 39.9%
-- Gross profit up 28.8%
-- Third consecutive year the Company has been cash-flow positive
-- 2009 Net Profit up $270,000 over 2008
For the twelve-month period ended December 31, 2009, Stellar's total revenues were $3,581,300. This compares to $2,559,400 in the same period in 2008 and was driven by 15.7% and 74.8% growth in Canadian and international sales, respectively. The gross margin percentage decreased to 66.6% in 2009 compared to 73.7% in 2008, largely as a result of the Company's continued strong growth in international sales where its margins are reduced. Net income for 2009, including $163,800 in non-cash stock options and amortization expenses (2008 - $140,200), was $238,900, or $0.01 per share, compared to a loss of $31,100, or ($0.01) per share, in 2008.
Stellar's strong financial performance allowed it to close the year in a solid financial position. As of December 31, 2009, the Company had cash and cash equivalents of $2,325,200. This was up from $2,106,000 at the end of 2008.
Peter Riehl, Stellar's President and Chief Executive Officer commented, "We are very pleased to show a profit for 2009 and a strong growth in our overall business, given the difficult economic environment that persisted for much of the year. Now, as we move forward into 2010, our focus will remain on building the Canadian business and expanding global licensing of Uracyst® and NeoVisc®. At the same time, we will continue to carefully manage our resources while pursuing opportunities for Stellar's future growth.
About Stellar Pharmaceuticals Inc.
Stellar has developed and is marketing direct in Canada, and in countries around the world through out-license agreements, three products based on its core polysaccharide technology: NeoVisc® and NeoVisc® Single Dose, for the symptomatic treatment of osteoarthritis; and Uracyst®, its patented technology for the treatment of interstitial cystitis (IC), an inflammatory disease of the urinary bladder wall. Both NeoVisc and Uracyst have their CE Mark certification for the European Community. Stellar also has an in-licensing agreement for NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. For more information, please visit the company's website at www.stellarpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
STELLAR PHARMACEUTICALS INC.
BALANCE SHEETS
(Expressed in Canadian dollars)
December 31
ASSETS 2009 2008
CURRENT
Cash and cash equivalents $ 2,325,212 $ 2,105,966
Accounts receivable, net of allowance of $nil
(2008 - $nil) 293,565 549,055
Inventories 721,061 364,551
Taxes recoverable 1,501 212,445
Loan receivable 15,818 18,369
Prepaids, deposits and sundry receivables 163,698 130,515
-------------- --------------
Total current assets 3,520,855 3,380,901
PROPERTY, PLANT AND EQUIPMENT 1,390,296 1,270,257
OTHER ASSETS 114,553 65,495
-------------- --------------
Total assets $ 5,025,704 $ 4,716,653
-------------- --------------
-------------- --------------
LIABILITIES
CURRENT
Accounts payable $ 228,367 $ 173,812
Accrued liabilities 175,637 186,201
Deferred revenues 2,890 1,749
-------------- --------------
Total current liabilities 406,894 361,762
-------------- --------------
CONTINGENCIES AND COMMITMENTS
SHAREHOLDERS' EQUITY
CAPITAL STOCK
AUTHORIZED
Unlimited Non-voting, convertible redeemable
and retractable preferred shares
with no par value
Unlimited Common shares with no par value
ISSUED
23,480,040 Common shares (2008 - 23,702,540) 8,183,638 8,261,403
Nil Treasury shares (2008 - 147,500) - (51,625)
Additional Paid-in capital for
cancelled Common shares - 2,329
Additional Paid-in capital options -
outstanding 89,562 35,965
Additional Paid-in capital options -
expired 724,127 722,372
-------------- --------------
8,997,327 8,970,444
DEFICIT (4,378,517) (4,615,553)
-------------- --------------
Total shareholders' equity 4,618,810 4,354,891
-------------- --------------
Total liabilities and shareholders' equity $ 5,025,704 $ 4,716,653
-------------- --------------
-------------- --------------
STELLAR PHARMACEUTICALS INC.
STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(Expressed in Canadian dollars)
FOR THE YEARS ENDED DECEMBER 31
2009 2008
------------- --------------
PRODUCT SALES $ 3,000,062 $ 2,118,282
ROYALTIES & LICENSING REVENUE 581,230 441,130
------------- --------------
TOTAL REVENUE FROM ALL SOURCES 3,581,292 2,559,412
COST OF PRODUCTS SOLD 1,001,871 556,401
------------- --------------
GROSS PROFIT 2,579,421 2,003,011
EXPENSES
Selling, general and administrative 2,278,530 2,010,383
Research and development 18,107 62,727
Amortization of assets (non-manufacturing
property, plant and equipment) 55,822 54,384
------------- --------------
2,352,459 2,127,494
------------- --------------
INCOME (LOSS) FROM OPERATIONS 226,962 (124,483)
INTEREST AND OTHER INCOME 11,962 83,741
GAIN ON DISPOSAL OF EQUIPMENT - 9,676
------------- --------------
NET INCOME (LOSS) AND COMPREHENSIIVE INCOME
(LOSS) FOR THE YEAR (before tax) 238,924 (31,066)
INCOME TAXES - -
------------- --------------
NET INCOME (LOSS) AND COMPREHENSIVE INCOME
(LOSS) $ 238,924 $ (31,066)
------------- --------------
------------- --------------
EARNINGS (LOSS) PER SHARE - Basic $ 0.01 $ (0.00)
------------- --------------
------------- --------------
- Diluted $ 0.01 $ -
------------- --------------
------------- --------------
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING - Basic 23,498,889 23,801,450
------------- --------------
------------- --------------
- Diluted 23,599,170 23,801,450
------------- --------------
------------- --------------
STELLAR PHARMACEUTICALS INC.
STATEMENTS OF CASH FLOWS
(Expressed in Canadian dollars)
FOR THE YEARS ENDED DECEMBER 31
2009 2008
------------- --------------
CASH FLOWS USED IN OPERATING ACTIVITIES
Net income (loss) $ 238,924 $ (31,066)
Items not affecting cash
Amortization 108,492 126,556
Gain on disposal of equipment - (9,676)
Write-down of property, plant & equipment - 2,656
Unrealized foreign exchange (gain) loss 24,203 (17,945)
Issuance of equity instruments for services
rendered 55,352 13,618
Change in non-cash operating assets and
liabilities 26,143 (562,256)
------------- --------------
CASH FLOWS USED IN OPERATING ACTIVITIES 453,114 (478,113)
CASH FLOWS PROVIDED BY (USED IN) INVESTING
ACTIVITIES
Additions to property, plant and equipment (155,630) (539,511)
Increase in other assets (26,230) (11,420)
Proceeds from sale of equipment - 10,000
------------- --------------
CASH FLOWS USED IN INVESTING ACTIVITIES (181,860) (540,931)
------------- --------------
CASH FLOWS USED IN FINANCING ACTIVITIES
Repurchase of common shares for cash (30,357) (100,514)
------------- --------------
CASH FLOWS USED IN FINANCING ACTIVITIES (30,357) (100,514)
------------- --------------
EFFECT OF EXCHANGE RATES ON CASH HELD IN
FOREIGN CURRENCY (21,650) 14,398
----------------------------
CHANGE IN CASH AND CASH EQUIVALENTS 219,246 (1,105,160)
CASH AND CASH EQUIVALENTS, beginning of year 2,105,966 3,211,126
----------------------------
CASH AND CASH EQUIVALENTS, end of year $ 2,325,212 $ 2,105,966
------------- --------------
------------- --------------
Contact:
Contacts:
Company Contact: Stellar Pharmaceuticals Inc.
Peter Riehl
President & CEO
(519) 434-1540
corpinfo@stellarpharma.com
Stellar Pharmaceuticals Inc.
Arnold Tenney
Chairman
(416) 587-3200
Investor Contact: Kilmer Lucas Inc.
Stephen Kilmer
President
(905) 690-2400 ext. 21
stephen@kilmerlucas.com
Media Contact: Kilmer Lucas Inc.
Leonard Zehr
Managing Director
(905) 690-2400 ext. 41
len@kilmerlucas.com
Buzz up! 0
SendSharePrint
Sponsored Links
Chicago
Can You Type? Earn $74+/hr From Home. Seen On CNN & FOX News.
HoustonFinanceNews.com
Top Stories
Oil above $82 as traders eye US supplies, OPEC - AP
EU warns 5 major eurozone nations on budgets - AP
Stock futures point toward higher opening - AP
OPEC insider: no change in output - AP
ADVERTISEMENT
Tech Ticker Recent Posts
"Big Shift": U.S. Economy Poised for Jobs Growth, John Challenger Says - Aaron Task
"Extended Period" Goes Into OT: Fed Stands Pat But Debate Lives On - Aaron Task
March Madness: Billion Dollar Time-Waster or Team-Building Opportunity? - Peter Gorenstein
Year of the Mac, Indeed: Apple Headed for a 2.9 Million Mac Quarter - John Paczkowski
China: If America Wants A Scapegoat For Its Problems, Don't Blame The Yuan, Blame Globalization - Vincent Fernando, CFA
View More
Subscribe to Topics
Top Stories
Add Alert
See all RSS links
ADVERTISEMENT
Copyright © 2010 CCNMatthews. CCNMatthews All rights reserved. All news releases provided by CCNMatthews are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.
YAHOO! FINANCE
Banking & Budgeting
Calculators
Currency
ETFs
Experts
Investing
Insurance
Market St
Did anyone see that interesting trading at the eod? There was a new MM involved.
Earnings should be anytime now. JMO
We just need to get the word out there about this company. It has a extremely low float and most of the outstanding is held by insiders.
There is no interest here. Earnings should be in the next few days, but that usually doesn't have an effect on the share price. We need to spread the word.
Here's an update.
Stellar outlines strategy at Cowen conference; gets Chinese patent
March 8, 2010 by stephenkilmer · Leave a Comment
Upcoming milestones for Stellar Pharmaceuticals (OTCBB:SLXCF (0.85 ?6.25%)) provide for near-and mid-term investment triggers, President and CEO, Peter Riehl, said in a presentation at the SG Cowen healthcare conference in Boston.
Stellar, which is only one of three Canadian companies presenting at the Cowen conference, is aggressively expanding its global out-licensing programs for its two lead products – Uracyst for the treatment of interstitial cystits/painful bladder syndrome (IC/PBS) and NeoVisc for osteoarthritis.
At the same time, Stellar is working with its U.S. partner for Uracyst, Watson Pharmaceuticals (WPI 40 ?1.38%) (NYSE:WPI), towards FDA approval and subsequent U.S. commercial launch. It is also on the hunt to acquire new products or companies.
Industry sources say Stellar’s appearance at the Cowan conference and its arrival on investors’ radar screens reflects the fact that Uracyst is gaining a competitive advantage over other less effective treatments for IC/PBS. New research suggests that chondroitin sulphate, the active ingredient in Uracyst, repairs defects in the bladder wall, known as the GAG layer, and re-establishes the bladder barrier function.
A webcast archive of Mr. Riehl’s presentation at the Cowen conference can be accessed here.
Separately, Stellar reported that the Chinese Patent Office has allowed a patent on Uracyst, which covers pharmaceutical compositions that comprise the greater and superior dosage sizes of chondroitin sulfate, and the use of those compositions for the treatment of IC/PBS. Once issued, the patent will expire on Feb. 18, 2024.
“With Uracyst patents already issued in Canada, the U.S. and Australia, and with numerous additional international patents pending, the Chinese patent expands Stellar’s already formidable intellectual property estate,” Mr. Riehl said in a statement.
“Along with our Shanghai-based marketing and distribution partner, Shanghai Ya Jun Medical Equipment Co. Ltd., we are very excited about commercially launching Uracyst in this important market pending Chinese State Food and Drug Administration approval,” he added.
Filed under Briefs · Tagged with NeoVisc, OTCBB, Peter Rihel, SLXCF, Stellar, Uracyst, Watston, WPI
Speak Your Mind
They release news via marketwire. Need to look on Yahoo. They are speaking as we speak at the conference right now. Should have an update later or tom on what was said.
We had nice news news this AM. Stellar will now hold a chinese patent for one of their main drugs. Lets get these guys going here.
Can anyone tell me why, there is no update on their relationship with LM in this report??
Hey Grapejuice I hear earning will be released after they present at the Cowen on the 8th. Should be steady as ever. Did $heff ever reply to you on stellar?
Who in their right minds would be selling at these levels? There is too much unsaid that should be uncovered fairly soon. This is way undervalued right here. JMO
Thats they way I felt when I bought this dog. I have been holding ever since. If and when I see even I'm out of here.
Look past this prior year. They have no regards toward their shareholder, and definitively not shareholder value! The only the thing they care about is their own pockets. Look at the end of the year trading and tell me that wasn't manupulated. Look at the filings by the insiders as well.JMO
I've been holding mine for over 5 years now. I really believe in their potential. Lets hope I'm right. I'm expecting some big things from these guys.
Thanks. For some reason I think you're right with AOL being off on their dates in the past. Lets hope it sooner, this needs a jump start right now. With no news this stock just drifts.
Can anyone confirm when the earnings will be released?
I've owned his stock for many years, and they just can't seem to get it together. They seem to be stuck in the mud. With a little self promotion people actually would find out who they are and what they do. I'm not looking for a pump but at least get yourself out there a little. Hopefully March 8th will get them some exposure.
Can someone update the ibox to reflect the current share structure.